Literature DB >> 2664738

Estrogen therapy and liver function--metabolic effects of oral and parenteral administration.

B von Schoultz1, K Carlström, L Collste, A Eriksson, P Henriksson, A Pousette, R Stege.   

Abstract

Oral estrogen therapy for prostatic cancer is clinically effective but also accompanied by severe cardiovascular side effects. Hypertension, venous thromboembolism, and other cardiovascular disorders are associated with alterations in liver metabolism. The impact of exogenous estrogens on the liver is dependent on the route of administration and the type and dose of estrogen. Oral administration of synthetic estrogens has profound effects on liver-derived plasma proteins, coagulation factors, lipoproteins, and triglycerides, whereas parenteral administration of native estradiol has very little influence on these aspects of liver function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2664738     DOI: 10.1002/pros.2990140410

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  13 in total

1.  Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?

Authors:  Syed Imran A Shah; Hannah C P Wilson; Paul D Abel
Journal:  Nat Rev Urol       Date:  2017-08-08       Impact factor: 14.432

2.  Impact of 17β-estradiol on complex I kinetics and H2O2 production in liver and skeletal muscle mitochondria.

Authors:  Maria J Torres; Terence E Ryan; Chien-Te Lin; Tonya N Zeczycki; P Darrell Neufer
Journal:  J Biol Chem       Date:  2018-09-14       Impact factor: 5.157

3.  Estrogen in patients with prostatic cancer. An assessment of the risks and benefits.

Authors:  P Henriksson
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

4.  Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.

Authors:  Ruth E Langley; Ian F Godsland; Howard Kynaston; Noel W Clarke; Stuart D Rosen; Rachel C Morgan; Philip Pollock; Roger Kockelbergh; El-Nasir Lalani; David Dearnaley; Mahesh Parmar; Paul D Abel
Journal:  BJU Int       Date:  2008-04-16       Impact factor: 5.588

5.  The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer.

Authors:  N Brunner; M Spang-Thomsen; K Cullen
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.

Authors:  Mark Stein; Susan Goodin; Susan Doyle-Lindrud; Jeffery Silberberg; Michael Kane; Dorinda Metzger; Simantini Eddy; Weichung Shih; Robert S DiPaola
Journal:  Med Sci Monit       Date:  2012-04

Review 7.  Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer.

Authors:  Syed Imran Ali Shah
Journal:  South Asian J Cancer       Date:  2015 Apr-Jun

8.  Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.

Authors:  Iain Phillips; Syed I A Shah; Trinh Duong; Paul Abel; Ruth E Langley
Journal:  Oncol Hematol Rev       Date:  2014

9.  Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).

Authors:  Ruth E Langley; Fay H Cafferty; Abdulla A Alhasso; Stuart D Rosen; Subramanian Kanaga Sundaram; Suzanne C Freeman; Philip Pollock; Rachel C Jinks; Ian F Godsland; Roger Kockelbergh; Noel W Clarke; Howard G Kynaston; Mahesh Kb Parmar; Paul D Abel
Journal:  Lancet Oncol       Date:  2013-03-04       Impact factor: 41.316

10.  Parenteral oestrogen in the treatment of prostate cancer: a systematic review.

Authors:  G Norman; M E Dean; R E Langley; Z C Hodges; G Ritchie; M K B Parmar; M R Sydes; P Abel; A J Eastwood
Journal:  Br J Cancer       Date:  2008-02-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.